Choice of catecholamine: Does it matter?

Current Opinion in Critical Care

Volumn 6, Issue 5, 2000, Pages 347-353

  Steel, Alan ^a   Bihari, David ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE DERIVATIVE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; HYDROCORTISONE; NORADRENALIN; PHENYLEPHRINE; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART FAILURE; HEMODYNAMICS; HUMAN; INTENSIVE CARE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTIC SHOCK;

EID: 0033809862     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200010000-00008     Document Type: Review

References (44)

1. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor
2. Epinephrine and related compounds: Influence of structure on physiological activity
3. Mutagenesis of the beta 2-adrenergic receptor: How structure elucidates function
4. Mammalian membrane-bound adenylyl cyclases
5. 'Working draft' of human genome available by June
6. Regulation of adenylyl cyclase-coupled beta-adrenergic receptors
7. Epinephrine impairs splanchnic perfusion in septic shock
8. Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock
9. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock
10. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: A prospective, randomized study
11. Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock
12. Abnormalities of gastric mucosal oxygenation in septic shock: Partial responsiveness to dopexamine
13. Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock
14. Porcine hepatic response to sepsis and its amplification by an adrenergic receptor alpha1 agonist and a beta2 antagonist
15. Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock
16. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock
17. The effects of low-dose dopamine infusions on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline
18. Dobutamine administration in septic shock: Addition to a standard protocol
19. Selective vasodilators redistribute intestinal blood flow depress oxygen uptake
20. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients
21. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock
22. Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: A prospective, multicenter study
23. A dobutamine test can disclose hepatosplanchnic hypoperfusion in septic patients
24. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
25. Improvement by acetylcysteine of hemodynamics oxygen transport in fulminant hepatic failure
26. Effects of a nitric oxide synthase inhibitor in humans with septic shock
27. Multi centr, randomised, placebo controlled, double blind study of the nitric oxide inhibitor 546C88: Effect on survival in patients with septic shock
28. Apoptosis in myocytes in end-stage heart failure
29. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
30. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure
31. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial
32. Pharmacology of bipyridine phosphodiesterase III inhibitors
33. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
34. Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors
35. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure
36. Intermittent inotropes for advanced heart failure: Inquiring minds want to know
37. Introduction: Positive inotropy by calcium sensitisation: An evolving approach for the treatment of end stage heart failure
38. Oral levosimendan increases cardiac function haemodynamics in patients with severe congestive heart failure
39. Levosimendan, a novel myofilament sensitiser allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure
40. Dose ranging and safety with intravenous levosimendan in low output cardiac failure. Experience in three pilot studies and outline of the levosimendan versus dobutamine (LIDO) trial
41. IV milrinone for cardiac output increase and maintenance: Comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure
42. Tumor necrosis factor alpha interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum
43. Low-dose vasopressin in the treatment of vasodilatory septic shock
44. Is it time to reposition vasopressors inotropes in sepsis?